Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6TFV

Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18b

Summary for 6TFV
Entry DOI10.2210/pdb6tfv/pdb
DescriptorEpidermal growth factor receptor, ~{N}-[5-[4-[[3-chloranyl-4-(pyridin-2-ylmethoxy)phenyl]amino]-7~{H}-pyrrolo[2,3-d]pyrimidin-5-yl]-2-(2-hydroxyethyloxy)phenyl]propanamide, 1,2-ETHANEDIOL, ... (6 entities in total)
Functional Keywordsher2, egfr, covalent inhibitors, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight77651.76
Authors
Niggenaber, J.,Mueller, M.P.,Rauh, D. (deposition date: 2019-11-14, release date: 2020-09-30, Last modification date: 2024-01-24)
Primary citationLategahn, J.,Hardick, J.,Grabe, T.,Niggenaber, J.,Jeyakumar, K.,Keul, M.,Tumbrink, H.L.,Becker, C.,Hodson, L.,Kirschner, T.,Klovekorn, P.,Ketzer, J.,Baumann, M.,Terheyden, S.,Unger, A.,Weisner, J.,Muller, M.P.,van Otterlo, W.A.L.,Bauer, S.,Rauh, D.
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
J.Med.Chem., 63:11725-11755, 2020
Cited by
PubMed Abstract: Mutated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward the inhibition of its family member epidermal growth factor receptor with small-molecule inhibitors. To date, small-molecule inhibitors targeting Her2 which can be used in clinical routine are lacking, and therefore, the development of novel inhibitors was undertaken. In this study, the well-established pyrrolopyrimidine scaffold was modified with structural motifs identified from a screening campaign with more than 1600 compounds, which were applied against wild-type Her2 and its mutant variant Her2-A775_G776insYVMA. The resulting inhibitors were designed to covalently target a reactive cysteine in the binding site of Her2 and were further optimized by means of structure-based drug design utilizing a set of obtained complex crystal structures. In addition, the analysis of binding kinetics and absorption, distribution, metabolism, and excretion parameters as well as mass spectrometry experiments and western blot analysis substantiated our approach.
PubMed: 32931277
DOI: 10.1021/acs.jmedchem.0c00870
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.5 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon